There is no clear data on the cure rate of non-Hodgkin’s lymphoma, but the cure rate of non-Hodgkin’s lymphoma in different prognostic subgroups can be judged by the 5-year survival rate.
The main manifestations of non-Hodgkin’s lymphoma include painless, progressive lymph node enlargement, or localized mass, often accompanied by systemic symptoms, and characterized by rapid progression.
Non-Hodgkin’s lymphoma is divided into 4 categories based on its international prognostic index. The 5-year survival rate of the low-risk group is about 73%; the 5-year survival rate of the low-intermediate-risk group is about 50%; the 5-year survival rate of the high-intermediate-risk group is about 43%; and the 5-year survival rate of the high-risk group is about 26%.
Lymphoma is currently one of the tumors that can be cured by chemotherapy. However, lymphoma is divided into many specific types, and the treatment options and prognosis vary greatly from one type to another. With the application of many new drugs, especially targeted drugs and immunotherapy, the cure rate of many types of non-Hodgkin’s lymphoma has also significantly improved. Therefore, it is recommended that patients standardize their treatment as early as possible, which is conducive to improving the remission and cure rates and restoring their health.